Background : The mammalian target of rapamycin (mTOR) regulates multiple cellular functions including translation in response to nutrients, especially amino acids. AMP-activated protein kinase (AMPK) modulates metabolism in response to energy demand by responding to changes in AMP.
Introduction
The target of rapamycin proteins, TOR1 and TOR2, were first identified in Saccharomyces cerevisiae through mutants that confer resistance to growth inhibition induced by the immunosuppressive macrolide rapamycin (Heitman et al . 1991; Abraham & Wiederrecht 1996) . Rapamycin binds to its intracellular receptor, the FK506-binding protein (FKBP12), and the FKBP12-rapamycin complex inhibits TOR function through direct binding to TOR in vivo (Stan et al . 1994; Zheng et al . 1995; Hall 1996) .
Early findings in S. cerevisiae have indicated that TOR1 and TOR2 participate in the control of translational initiation and early G1 progression in response to nitrogen availability (Di Como & Arndt 1996; Schmelzle & Hall 2000) . Additional functions of TOR include the regulation of transcription, amino acid uptake, cytoskeletal organization and protein degradation through autophagy (Schmelzle & Hall 2000; Schmidt et al . 1998) . TOR orthologues have been identified in mammals (mTOR, also known as FRAP, RAFT1 or RAPT) (Avruch et al . 2001 ). The C-terminus of mTOR kinase is most closely related to the phosphatidylinositol kinase (PIK) subfamily, which plays important roles in controlling the cell cycle that includes ATM, ATR and DNA-PK .
In cultured mammalian cells, rapamycin blocks the phosphorylation of several translational regulators, including eukaryotic initiation factor-4E binding protein 1 (4E-BP1) (Lawrence & Abraham 1997; Beretta et al . 1996) and p70 S6 kinase (p70 S6k) (Chung et al . 1992; Price et al . 1992) . Furthermore, mTOR is an upstream regulator of these translational effectors (Lawrence & Abraham 1997; Hara et al . 1997; Brown et al . 1995) .
The activity of p70 S6k dramatically increases through multisite phosphorylation in response to insulin or mitogens in vivo (Avruch et al . 2001 ). p70 S6k is thought to play an important role in the translation of a subclass of mRNAs containing a short oligopyrimidine sequence ( Jefferies et al . 1997) , although this has been recently challenged (Tang et al . 2001) . In addition to regulation by insulin or mitogens, nutrients, especially amino acids, have been discovered to regulate the phosphorylation of p70 S6k and 4E-BP1 and to be necessary for the insulin or mitogen regulation of these targets by mTOR (Hara et al . 1998; Wang et al . 1998; Patti et al . 1998; Fox et al . 1998; Shigemitsu et al . 1999; Xu et al . 1998) . Several studies of Drosophila melanogaster TOR have demonstrated that TOR proteins play a critical role in controlling cell growth by regulating several translational effectors in response to the nutritional environment (Oldham et al . 2000; Zhang et al . 2000; Montagne et al . 1999) .
As well as nitrogen, carbon is the most basic nutrient source for cellular organisms. Carbon is used to produce energy and synthesize a wide range of biomolecules. In the yeast S. cerevisiae , in addition to the role of carbon in energy metabolism and metabolic biosynthesis, the presence of carbon, such as that in glucose, represses the expression of genes involved in the transport and utilization of other carbon sources. This is commonly known as glucose repression (Carlson 1999) . Gene de-repression is mediated by activation of the Snf1 protein kinase. When glucose is limiting, Snf1 is activated and the transcription of many glucose-repressed genes is switched on .
AMP-activated protein kinase (AMPK) is the mammalian orthologue of Snf1 Kemp et al . 1999 ) and exists as a heterotrimetric complex comprising a catalytic α subunit and non-catalytic β and γ subunits Kemp et al . 1999) . Under conditions of hypoxia, exercise, ischaemia, heat shock and low glucose, AMPK is activated allosterically by rising cellular AMP and by phosphorylation of the catalytic α subunit by one or more AMPK kinases on Thr-172, located in the 'T-loop' of the catalytic domain Kemp et al . 1999) . Once activated, AMPK phosphorylates multiple downstream substrates aimed at conserving existing ATP levels. AMPK reduces further ATP expenditure by inhibiting key enzymes in biosynthetic pathways such as acetyl-CoA carboxylace in fatty acid synthesis and 3-hydroxy-3-methyl-CoA reductase in cholesterol synthesis . AMPK also increases the supply of ATP, for example by stimulating the rate of fatty acid oxidation and cellular glucose uptake .
In the present study, in order to identify novel mTOR-interacting proteins, yeast two-hybrid screening was carried out using the catalytically inactive mutant of mTOR kinase domain as a bait, revealing the AMPK γ 1 subunit as a putative mTOR-interacting protein. This led us to examine the possible relationship between the AMPK and mTOR/amino acid signalling pathways. The results demonstrate that modulation of AMPK activities using various reagents, including 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), d -glucose and its analogues, and mutant AMPK subunits, affects the activity and phosphorylation state of p70 S6k, indicating a convergence of AMPK signalling and mTOR/amino acid signalling pathways on to p70 S6k.
Results

Inhibition of endogenous p70 S6k activity by AICAR in different cell lines
To investigate mTOR-interacting proteins, yeast twohybrid screening was carried out using mTOR kinase domain as a bait. We isolated several independent cDNA clones encoding the carboxyl terminal of the γ 1 subunit of mammalian AMPK (amino acids 256-331). A portion of the γ 1 subunit, which was isolated by yeast twohybrid screening, was found to specifically bind to both the wild-type and the catalytically inactive mutant of mTOR kinase domain in HEK293 cells. However, we could not observe any interactions between the full length of mTOR and the γ 1 subunit. Nevertheless, it was of interest to test for a possible relationship between the AMPK and mTOR/amino acid signalling pathways. In order to investigate whether AMPK is involved in the mTOR/amino acid signalling pathway, the effects of AICAR, an activator of AMPK, on p70 S6k activities were examined in several cell lines including SV40-immortalized human corneal epithelial cells (HCE-T cells), H-4-II-E rat hepatoma cells (H4IIE cells), Chinese Hamster Ovary cells over-expressing human insulin receptors (CHO-IR cells), and HEK293 cells (Fig. 1 ). Cells were deprived of serum for 16 h, followed by incubation with a fresh serum-free medium for 1 h and then treatment with 1 m m AICAR for 1 h. In HCE-T cells and H4IIE cells, treatment with AICAR caused an 80% inhibition of p70 S6k activities compared with the control (Fig. 1 , top two panels, compare lanes 1 with 2), while in CHO-IR cells and HEK293 cells, no obvious effect of AICAR was observed (Fig. 1 , bottom two panels, compare lanes 1 with 2). We investigated whether the p70 S6k activation induced by insulin was also inhibited by AICAR. Insulin-induced p70 S6k activation was partially inhibited in HCE-T cells and H4IIE cells (Fig. 1 , top two panels, compare lanes 3 with 4) but not in CHO-IR cells and HEK293 cells (Fig. 1 , bottom two panels, compare lanes 3 with 4). As expected, treatment of cells with rapamycin completely abolished p70 S6k activity in all cell lines (Fig. 1, lane 5) . These results indicated that AMPK may be involved in p70 S6k regulation, at least in HCE-T cells and H4IIE cells. We therefore employed HCE-T cells for further studies to investigate the involvement of AMPK in mTOR/amino acid signalling.
Inhibition of p70 S6k activity by AICAR in HCE-T cells
HCE-T cells were deprived of serum for 16 h, followed by incubation with a fresh serum-free medium for 1 h and then treatment with the indicated concentration of AICAR for 1 h ( Fig. 2A,B) or with 1 m m AICAR for the indicated time periods (Fig. 2C,D) . The treatment with AICAR inhibited p70 S6k activities in a dose-and time-dependent manner. Approximate 70% and 80% reductions of the p70 S6k activities were observed following treatment with 2 m m AICAR for 1 h ( Fig. 2A) or with 1 m m AICAR for 2 h (Fig. 2C) , respectively. As expected (Fig. 2B,D) , AMPK was activated by AICAR in a dose-and time-dependent manner. It should be noted that we report AMPK activities in immunoprecipitates of AMPK α 1-containing heterotrimers; no AMPK α 2 containing heterotrimers could be detected in these cells (data not shown). Three-to six-fold activation of AMPK was observed by the treatment with 2 m m AICAR for 1 h (Fig. 2B ) or with 1 m m AICAR for 2 h (Fig. 2D) , respectively. In H4IIE cells, the same inhibitory effects of AICAR on p70 S6k activities were observed (data not shown).
Modulation of p70 S6k activity by glucose availability in HCE-T cells
In rat pancreatic islet cells, glucose withdrawal leads to a large increase in cellular AMP/ATP ratio, thereby activating AMPK. Re-addition of glucose causes a reduction of AMPK activity (Salt et al . 1998; Hamilton et al . 2002) . Thus, to further explore the involvement of AMPK in mTOR/amino acid signalling, we investigated the effects of glucose availability on p70 S6k activities in HCE-T cells. HCE-T cells were deprived of serum for 16 h, followed by incubation with a fresh serum-free medium for 1 h and then transferred to . In panels A and C, activities of p70 S6k were assayed after immunoprecipitation as described under Experimental procedures.
In panels B and D, immunopurified AMPK was subjected to the kinase assay as described under Experimental procedures. All assays were performed in duplicate. The activity of p70 S6k obtained from control cells, which are not treated with AICAR, were regarded as control (= 100%) (panels A and C).
Relative activity of the mean value at the indicated conditions was calculated and expressed as percentage at the bottom of each lane. The activity of AMPK obtained from control cells, which are not treated with AICAR, were regarded as control. A ratio of the mean value of AMPK activities at the indicated conditions to the control was calculated and kinase activity is indicated as fold-activation relative to the control value. The values shown represent the ranges of duplicate incubations at each condition and are representative of three experiments of this type.
glucose-free medium. Glucose withdrawal inhibited p70 S6k activities for up to 30 min in time-dependent manner ( Fig. 3A) . As expected, AMPK was rapidly activated by glucose withdrawal and the activation was sustained for up to 1 h (Fig. 3B ). Moreover, re-addition of 5.5 mm glucose to the glucose-free medium rapidly restored p70 S6k activity and simultaneously inhibited AMPK within 5 min (Fig. 3C,D) . Taken together, the effects of AICAR and of glucose availability on p70 S6k activities are consistent with the interpretation that, either directly or indirectly, AMPK regulates p70 S6k activities. There is a slight temporal discrepancy between effects of glucose withdrawal and AICAR after 30 min (Fig. 3A ,B). Although glucose withdrawal caused sustained activation of AMPK, p70 S6k activities slightly increased back toward initial values after 30 min.
Phosphorylation and activation of p70 S6k, phosphorylation of protein kinase B (PKB), and activation of AMPK under various nutritional conditions in the presence or absence of insulin and AICAR
p70 S6k activities in HCE-T cells were next examined under various nutritional conditions in the presence or absence of insulin and/or AICAR. HCE-T cells were deprived of serum for 16 h, followed by incubation with a fresh serum-free medium for 1 h, and then incubated with a fresh serum-free medium containing glucose and/or amino acids or lacking both nutrients. The activity of p70 S6k in serum-deprived HCE-T cells was still observed in the presence of both amino acids and glucose (Fig. 4A , lane 1). In contrast, it was reduced in In panels A and C, activities of p70 S6k were assayed after immunoprecipitation as described under Experimental procedures. In panels B and D, immunopurified AMPK was subjected to the kinase assay as described under Experimental procedures. All assays were performed in duplicate. In (A) the activity of p70 S6k at 0 min was taken as a control (= 100%). The relative activity of the mean value at indicated times to the control was calculated and expressed as a percentage at the bottom of each lane. The activity of AMPK obtained from control cells, which are not treated with AICAR, were taken as a control. A ratio of the mean value of AMPK activities at the indicated conditions to the control was calculated and kinase activity is indicated as fold-activation relative to the control value. The values shown represent the ranges of duplicate incubations at each condition and are representative of three experiments of this type.
the presence of glucose alone (Fig. 4A , lane 4) or in the absence of both amino acids and glucose (Fig. 4A, lane  7) . The same inactivation of the activity of p70 S6k was also observed in the presence of amino acids alone (data not shown). The treatment of HCE-T cells with 100 nm insulin for 10 min (in the presence of amino acids and glucose) caused a four-fold activation of p70 S6k ( Effects of nutrients, insulin, and /or AICAR on p70 S6k, PKB and AMPK activities. HCE-T cells were incubated in serumfree DMEM/F-12 for 16 h, then replaced in fresh serum-free MEM AA(+)/G(+) (lanes 1-3), serum-free MEM AA(-)/G(+) (lanes 4 -6), or serum-free MEM AA(-)/G(-) (lanes 7, 8), respectively, for 120 min. Cells were treated with 100 nm insulin for the last 10 min (lanes 2, 5, 8). Cells were treated with 1 mm AICAR for the last 60 min prior to the addition of 100 nm insulin for the last 10 min (lanes 3, 6). (A) Activities of p70 S6k were assayed after immunoprecipitation as described under Experimental procedures. The activity of insulininduced activation of p70 S6k in serum-free MEM AA(+)/G(+) (lane 2) was regarded as a control (= 100%). Relative activity of the mean value to the control at indicated conditions was calculated and expressed as a percentage at the bottom of each lane. (B) The same amount of extracts from HCE-T cells was used for immunoblot analysis. Phosphorylation of p70 S6k on Thr-412 was examined using an anti-p70 S6k (pT412)-specific antibody (top panel). Total amounts of p70 S6k were shown in second panel. Phosphorylation of PKB on Ser-473 was examined using an anti-PKB (pS473)-specific antibody (third panel). Total amounts of PKB are shown in bottom panel. (C) Immunopurified AMPK was subjected to the kinase assay as described under Experimental procedures. The activity of AMPK obtained in lane 1 was regarded as control. A ratio of the mean value of AMPK activities at the indicated conditions to the control was calculated and kinase activity is indicated as fold-activation relative to the control value. The values shown represent the ranges of duplicate incubations at each condition and are representative of three experiments of this type.
HCE-T cells in the presence of glucose alone also led to p70 S6k activation (Fig. 4A, lane 5) . The ability of insulin to stimulate p70 S6k activity was retained in the presence of amino acids alone (data not shown). However, the ability of insulin to stimulate p70 S6k activity was completely abolished in the absence of amino acids and glucose (Fig. 4A, lane 8) .
The pre-treatment of HCE-T cells with 1 mm AICAR for 1 h caused an approximate 70% inhibition of insulin-induced activation of p70 S6k in the presence of amino acids and glucose (Fig. 4A , compare lanes 2 with 3) or in the presence of glucose alone (Fig. 4A , compare lanes 5 with 6). Among these culture conditions, both the addition of AICAR and the withdrawal of glucose caused the activation of AMPK (Fig. 4C, lanes 3, 6, 7 and 8). These findings are also consistent with the idea that the activation of AMPK negatively regulates p70 S6k activity. p70 S6k is activated by insulin and mitogens in vivo through coordinate phosphorylation at multiple sites. Among multiple phosphorylation sites, phosphorylation of Thr-412 in the kinase extension domain of p70 S6kα is indispensable for p70 S6k activity (Dennis et al. 1996) . Thus, in order to confirm the activation state of p70 S6k, immunoblotting of p70 S6k using anti-phosphothreonine 412 of p70 S6k antibodies was carried out (Fig. 4B, top  panel) . In agreement with the results shown in Fig. 4A , the immunoreactivity with the anti-p70 S6k (pT412)-specific antibody was decreased during AICAR treatment (Fig. 4B , top panel, compare lanes 2 with 3, or lanes 5 with 6), amino acid withdrawal (Fig. 4B , top panel, compare lanes 4 with 1) or withdrawal of amino acids and glucose in the absence or presence of insulin (Fig. 4B, top panel, compare lanes 7, 8 with lane 1) . In contrast to these results, immunoreactivities of antiphosphoserine 473 of protein kinase B (PKB) antibodies, the phosphorylation of which is critical for its activity (Alessi 2001) , were increased after insulin stimulation (Fig. 4B, third panel, lanes 2, 5 and 8) , even after the treatment with AICAR (Fig. 4B, third panel, lanes 3 and  6) . These data indicate that effects of AICAR and withdrawal of nutrients target p70 S6k, but not PKB.
Resistance of rapamycin-resistant p70 S6k variant to inhibition caused by AICAR
The selective inhibition of p70 S6k that occurs consequent to AICAR treatment or glucose withdrawal corresponds closely to the cellular response seen following the addition of rapamycin. The similar selectivity of the cellular response to AICAR and glucose withdrawal, and rapamycin led us to examine the effects of AICAR on the activity of a rapamycin-resistant p70 S6k variant, p70∆2-46/∆CT104 (Weng et al. 1995) . This variant was activated by insulin (Fig. 5A , compare lanes 5 with 6) as was the wild-type p70 S6k (Fig. 5A, compare lanes 1  with 2) . Like the wild-type p70 S6k (Fig. 5A , compare lanes 2 with 4), this p70 S6k variant was markedly inhibited by treatment of cells by wortmannin (Fig. 5A , compare lanes 6 with 8), but was quite resistant to inhibition by rapamycin (Fig. 5A, compares lanes 2 with 3,  lanes 6 with 7) . Treatment with 1 mm AICAR did not inhibit, but activated the activity of p70∆2-46/∆CT104 (Fig. 5B, right panel) in marked contrast to the significant inhibition of recombinant wild-type p70 S6k engendered by 1 mm AICAR treatment (Fig. 5B, left panel) . The unexpected activation of p70∆2-46/∆CT104 by AICAR treatment is reproducible. The mechanism of this phenomenon is, however, unknown. The resistance of p70∆2-46/∆CT104 to inhibition caused by both rapamycin and AICAR suggests that mTOR is required in order to mediate the inhibition of p70 S6k by these agents.
Effect of over-expression of mutant AMPK subunits, which alters AMPK activity, on p70 S6k activities AICAR has been widely used as an activator of AMPK but is not necessarily specific (Kemp et al. 1999) . Accordingly, we examined the effects of over-expression of mutant AMPK subunits, that alters AMPK activity, on p70 S6k activities. First we employed the constitutively active truncated form AMPKα1 (1-312) that does not require β and γ subunits for activity (Crute et al. 1998) . As shown in Fig. 6 , over-expression of GST-AMPKα1 (1-312) fragment in HCE-T cells resulted in 60% inhibition of recombinant p70 S6k activity compared with control (Fig. 6 , top panel, compare lanes 2 with 1).
We next undertook to investigate the regulation of p70 S6k in cell lines stably over-expressing mutant AMPK subunits which either activate or inhibit endogenous AMPK activity. Mutation of the γ1 subunit (R70Qγ1) causes a four-fold increase in AMPK activity when stably expressed in PS120 cells (Hamilton et al. 2001) . Stable over-expression of a mutant, inactive α1 subunit (K45Rα1) caused a marked inhibition of AMPK activity to < 2% of control values (data not shown) (Dyck et al. 1996) . As shown in Fig. 7A , immunoblotting of cell extracts from two cell lines over-expressing either HA-tagged R70Qγ1 or GST-tagged K45Rα1 confirmed these alterations in AMPK activity under basal conditions and after stimulation with AICAR. As shown in Fig. 7A , AICAR slowed the migration of AMPKα in the control line (NHE) (compare lanes 1 Figure 5 Insensitivity of rapamycin-resistant p70 S6k variant to AICAR. HCE-T cells were transfected with either a wild-type FLAG-p70 S6k or a rapamycin-resistant p70 S6k variant, FLAG-p70 S6k ∆2 -46/ ∆CT104. After transfection for 24 h, cells were deprived of serum for 16 h, and then replaced in fresh serum-free DMEM / F-12 for 1 h. (A) In lanes 2 and 6, cells were treated with 100 nm insulin for the last 10 min. In lanes 3 and 7, cells were treated with 200 nm rapamycin for the last 30 min prior to the addition of 100 nm insulin for the last 10 min. In lanes 4 and 8, cells were treated with 100 nm wortmannin for the 30 min prior to the addition of 100 nm insulin for the last 10 min. (B) Cells were treated with 1 mm AICAR for the indicated time periods. In (A) and (B), activities of FLAG-p70 S6k were assayed after immunoprecipitation with the anti-FLAG antibody as described under Experimental procedures. In the upper panel, autoradiograms of phosphorylated S6 protein were shown. In lower panel, total amounts of FLAG-p70 S6k were determined by immunoblotting using the anti-FLAG antibody. The activity of p70 S6k at 0 min was taken as a control (= 100%) and relative activity at indicated times to the control was calculated and expressed as the percentage shown in the bottom graph. These results are a representative of three reproducible experiments.
Figure 6
Co-transfection of p70 S6k and constitutively active AMPK α subunit. HCE-T cells were co-transfected with FLAGp70 S6k and either empty pEBG vector (lane 1) or constitutively active form of GST-tagged truncated AMPK α1 (lane 2). After transfection for 24 h, cells were deprived of serum for 16 h, and then replaced in fresh serum-free MEM AA(+)/G(+) for 1 h. Activities of FLAG-p70 S6k were assayed after immunoprecipitation with the anti-FLAG antibody as described under Experimental procedures. Incorporation of 32 P into S6 protein was shown in upper panel. The total amounts of immunoprecipitated FLAGp70 S6k were determined by Western blotting using the anti-FLAG antibody in middle panel. The expression of mutant AMPK subunit was determined by Western blotting using the anti-GST antibody in bottom panel.
with 2) due, in part, to altered an subunit phosphorylation on Thr-172 (Fig. 7C, compare lanes 1 with 2) . In the HA-R70Qγ1-over-expressing cell line (Fig. 7B,  lanes 3 and 4) , AMPK mobility and phosphorylation were altered even in the absence of AICAR stimulation, and changes were exaggerated after AICAR treatment (Fig. 7A,C, lanes 3 and 4) . In contrast, in the GST-K45Rα1 over-expressing cell line, expression of the endogenous AMPKα was markedly reduced (Fig. 7A , lanes 5 and 6). We have shown that this is due to an increased α turnover in the presence of this inactive subunit, which competes for binding of the endogenous β and γ subunits, increasing the degradation of native α (Crute et al. 1998) . This phenomenon has also been noted by others in a transgenic mouse model with a dominant negative α construct (Mu et al. 2001) . While the inactive GST-α fusion protein was phosphorylated on Thr-172 with a migration shift, active endogenous AMPK α, detected by migration shift and pThr-172, was markedly reduced (Fig. 7A,C , lanes 5 and 6), consistent with the marked decrease in measured enzyme activity (latter data not shown).
These cell lines were deprived of serum for 16 h, followed by incubation with a fresh serum-free medium for 1 h and then treatment with or without 1 mm AICAR for 1 h. In NHE cells, treatment with AICAR caused a 50% inhibition of p70 S6k activities (Fig. 7D, compare  lanes 1 with 2) . In HA-R70Qγ1-over-expressing cells, the basal activities of p70 S6k were reduced (Fig. 7D, compare  lanes 1 with 3) , and in the presence of AICAR this inhibition was strongly enhanced (Fig. 7D, compare lanes 3  with 4) . These results are consistent with constitutive activation of AMPK by stable over-expression of R70Qγ1. In contrast, in the GST-K45Rα1-over-expressing cells, Figure 7 p70 S6k regulation in stable cells lines with activated and inhibited AMPK. PS120 cells, stably expressing epitope-tagged mutant AMPK subunits (either HA-R70Qγ1 or GST-K45Rα1) were incubated for 2 h under basal conditions or after the addition of AICAR (1 mm). Cells were harvested and, as previously described (Hamilton et al. 2001) , extracts matched for proteins were separated by SDS-PAGE for immunoblotting. Extracts were blotted with the anti-AMPKα antibody (the antibody recognizing both α isoforms) (panel A), the anti-HA antibody (panel B) or the antibody specific for the pT172 active form of AMPK α (panel C). Each cell line was treated with vehicle (lanes 1, 3, 5) or 1 mm AICAR (lanes 2, 4, 6) for 1 h. Activities of p70 S6k were assayed after immunoprecipitation as described under Experimental procedures (panel D). Activities of p70 S6k at lane 1 was regarded as control (= 100%). Relative activity to the control at indicated conditions was calculated and expressed as percentage at the bottom of each lane. Autoradiograms of phosphorylated S6 protein were shown in upper panels. The total amounts of p70 S6k were examined using the anti-p70 S6k antibody in the lower panel.
both the basal activities and activities in the presence of AICAR of p70 S6k were increased (Fig. 7D , lanes 5 and 6) in agreement with the dominant-negative effect of K45Rα on AMPK activities. These results strongly support a molecular link between AMPK and the mTOR/ amino acid signalling pathways.
Effect of D-glucose withdrawal or substitution to D-glucose analogues on activities of AMPK and p70 S6k in HEK293 cells
As shown in Fig. 1 (bottom (Fig. 8B , upper panel, compare lanes 2 with 1) but not in HEK293 cells (Fig. 8B , lower panel, compare lanes 2 with 1). To gain some insight into a linkage between AMPK and p70 S6k in HEK293 cells, we explored whether d-glucose withdrawal or different dglucose analogues could modulate the activities of AMPK and p70 S6k in HEK293 cells. The non-physiological stereoisomer l-glucose can be neither transported nor metabolized. In contrast, the d-glucose analogue 2-deoxyglucose (2-DG) can be transported, but cannot be metabolized fully, thus inhibiting glycolysis. Withdrawal of d-glucose (Fig. 8, lane 3) or substitution of d-glucose to l-glucose (Fig. 8, lane 4) was able to activate AMPK and inhibit p70 S6k in HCE-T cells, but not in HEK293 cells. In contrast, the substitution of d-glucose to 2-DG was able to induce activation of AMPK and inhibition of p70 S6k in both HCE-T cells and HEK293 cells (Fig. 8, lane 5) .
Discussion
The present study provides evidence that the AMPK and mTOR signalling pathways are possibly linked. First, the treatment of AICAR, widely used as an AMPK activator, inhibits p70 S6k activities in a dose-and time-dependent manner in HCE-T cells (Fig. 2) . Second, the reagents or treatments that cause activation of AMPK, inhibit p70 S6k activities in many cell lines, even in HEK293 cells (Figs 1 and 8) . Third, altered glucose availability leads to the change of AMPK activities that modulates p70 S6k activities (Fig. 3) . Fourth, the treatment of AICAR also inhibit phosphorylation of Thr-412 in the kinase extension domain of p70 S6kα, which is indispensable for its kinase activities, but not Ser-473 of PKB (Fig. 4) . Fifth, rapamycin-resistant p70 S6k variant is also insensitive to AICAR (Fig. 5) . Sixth, over-expression of mutant AMPK subunits, which alter AMPK activities, modulates p70 S6k activities (Figs 6 and 7) .
Recently, it was reported that AMPK suppresses protein synthesis in rat skeletal muscle through downregulated PKB and mTOR signalling (Bolster et al. 2002) . This study utilized AICAR to activate AMPK. Since AICAR may have multiple cellular effects other than the activation of AMPK (Kemp et al. 1999) , more rigorous proof of a relationship is necessary to conclude that these effects are due to AMPK activity. In the present study, in addition to AICAR, d-glucose availability, d-glucose analogues, and mutant AMPK subunits were employed to activate or inhibit AMPK. The latter experiments support the idea that there is a possible molecular link between the mTOR and AMPK signalling pathways. Thus, while a truncated form of amino-terminal AMPKα1 or a mutant activating γ1 subunit (R70Qγ1), which causes a constitutive activation of AMPK activities, inhibits p70 S6k activities, an inactive α1 subunit mutant (K45Rα1), which induces a marked inhibition of AMPK activities, increases p70 S6k activities and blocks the inhibiting effects of AICAR (Figs 6 and 7) .
In the present study, we observed that HCE-T and H4IIE cells are sensitive to AICAR to inhibit p70 S6k but not CHO-IR cells and HEK293 cells (Fig. 1) . In CHO-IR cells, p70 S6k activity is sensitive to amino acid withdrawal and addition but not glucose (Hara et al. 1998) . Prior studies in our laboratory have shown that AICAR is unable to activate AMPK in HEK293 cells (L.A.W., unpublished observation). In HCE-T cells, the activation of AMPK and subsequent p70 inhibition is caused by d-glucose withdrawal and treatment of dglucose analogues, as well as AICAR treatment. In contrast, in HEK293 cells, only 2-DG is able to induce activation of AMPK and subsequent inhibition of p70 S6k (Fig. 8) . The glycolytic inhibitor 2-DG is likely to be effective in reducing ATP concentrations, raising the AMP/ATP ratio, and subsequently activating AMPK in HEK293 cells, because those cells predominantly use anaerobic respiration to produce ATP (Dennis et al. 2001) . Thus it is reasonable to suppose that the activation of AMPK leads to inhibition of p70 S6k even in HEK293 cells, suggesting that modulation of the mTOR signalling by AMPK signalling will be a generalized phenomena in cells, although the change of AMP/ATP ratio induced by various stimuli may vary among cell lines.
Recently, it has been reported that p70 S6k is inhibited by treatment with the mitochondrial inhibitors, azide, rotenone and carbonylcyanide m-chlorophenlyhydrazone (Dennis et al. 2001; Desai et al. 2002; Xu et al. 2001) . These results are similar to our present observations of inhibition of p70 S6k activities induced by AICAR, glucose withdrawal, d-glucose analogues and overexpression of mutant AMPK subunits, indicating that mitochondrial dysfunction caused by the mitochondrial inhibitors may inhibit p70 S6k by activating AMPK. In hepatocytes, ATP depletion resulting from incubation with fructose or glycerol, in addition to AICAR treatment, likewise has been reported to inhibit p70 S6k (Dubbelhuis & Meijer 2002) . Importantly, we have observed that rapamycin-resistant p70 S6k variant was insensitive to AICAR treatment. Previously the rapamycinresistant p70 S6k variant was found to be insensitive to the depletion of ATP levels caused by either 2-DG or mitochondrial inhibitors (Dennis et al. 2001; Desai et al. 2002) . Therefore it seems reasonable to conclude that AMPK acts as a common effector for the actions of AICAR, 2-DG, mitochondrial inhibitors and other ATP depletors by inhibiting the mTOR-mediated activation of p70 S6k. Dennis et al. (2001) have proposed that mTOR could function as an ATP sensor in eukaryotic cells through a direct regulation of its activity by varying the concentrations of ATP. However, it would seem that such a mechanism would be likely to only operate at the extremes of cellular ATP depletion, in that they report an ATP Km of approximately 1 mm for mTOR. The relationship between the mTOR signalling system and that of AMPK, irrespective of the molecular mechanism involved, would make mTOR sensitive to even minimal ATP depletion. Even small decrements in ATP can result in elevations of cellular AMP through the actions of adenylate kinase, leading to AMPK activation and p70 S6k inhibition.
In contrast to Bolster et al. we have not been able to confirm an effect of AICAR in reducing the phosphorylation of mTOR on Ser-2448 (data not shown). In addition, the lack of inhibition of PKB by AICAR (Fig. 4) clearly indicates that AMPK does not signal through PKB to modulate mTOR and its downstream effector. The mechanism underlying the AMPK mediated inhibition of mTOR signalling is not known. To date, we could not observe the effect of AICAR on mTOR intrinsic kinase activity toward 4E-BP1 in vitro (data not shown). In addition, we could not observe the interaction between the full-length of mTOR and the γ1 subunit of AMPK, although the C-terminal portion of both proteins were found to bind each other in HEK293 cells. This could be due to the differences in three-dimensional structures between the full-length of mTOR and the C-terminal portion of mTOR. Recently, raptor, a binding partner of mTOR which mediates mTOR action, was identified (Hara et al. 2002; Kim et al. 2002; Loewith et al. 2002) . AMPK also exists as a complex of α, β and γ subunits (Kemp et al. 1999) . Thus, if the ability of the mTOR-raptor complex to bind to the complete AMPK complex were examined, the discrepancies in the binding experiments might be clarified.
In conclusion, mTOR may not directly sense the intracellular level of ATP, but the AMPK sensing the intracellular level of AMP/ATP ratio could signal to p70 S6k. While the amino acid and mTOR signals may act as a priming switch to modulate p70 S6k activation, AMPK signal could play a role as another overriding switch for p70 S6k regulation in the distinct pathway from PKB. This idea is consistent with a recent study in S. cerevisiae which showed that Snf1-glucose signalling and TOR-nitrogen signalling pathways converge on to the GATA-type transcription factor Gln3 (Bertram et al. 2002) .
Experimental procedures
Antibodies and cDNA
The anti-HA antibody was purchased from Roche Molecular Biochemicals and the monoclonal ant-FLAG antibody (M2) was purchased from Sigma. The anti-GST antibody was from Upstate Biotechnology and the anti-p70 S6k antibody for Western blotting was purchased from Santa Cruz Biotechnology. The anti-PKB antibody was purchased from Transducion Laboratories. The anti-phosphothreonine 412 of p70 S6k antibodies and the antiphosphoserine 473 of PKB antibodies were from Cell Signalling Technology Inc. The anti-AMPK α1 antibody for immunoprecipitation was prepared using a synthetic peptide corresponding to the amino acid sequences for residues 339 -358 (DFYLATSPPDS-FLDDHHLTR) from AMPK α1. The anti-AMPK α1 antibody for Western blotting and anti-phosphopeptides antibodies against Thr-172 of AMPK α1 were purchased from Cell Signalling Technology Inc. The anti-p70 S6k antibody for immunoprecipitation was as previously described (Hara et al. 1997) .
The expression vectors of FLAG-tagged wild-type p70 S6kα (FLAG-p70 S6k, wild) and the rapamycin-resistant mutant of p70 S6kα (∆2 -46/∆CT104), and GST-tagged constitutive active form of rat AMPK α1 subunits (GST-AMPK α1(1-312)) were as previously described (Crute et al. 1998; Weng et al. 1995) . cDNA fragments encompassing nucleotides from 6441 to 7650 were amplified by PCR using wild-type mTOR (mTOR-WT) or kinase-negative mutant (mTOR-NK) as a template to create fragments encoding the wild-type (∆mTOR-WT) or kinasenegative (∆mTOR-NK) kinase domain of mTOR, respectively. Both cDNA fragments were ligated into the pCMV-FLAG vector to produce FLAG-tagged ∆mTOR-WT (FLAG-∆mTOR-WT) or ∆mTOR-NK (FLAG-∆mTOR-NK).
Yeast two-hybrid screen
The yeast two-hybrid screening was carried out using a fusion protein of the inactive mutant mTOR kinase domain (∆mTOR-NK) and the DNA-binding domain of prokaryotic LexA protein as a bait (Clontech Laboratories Inc., Palo Alto, CA) (Gyuris et al. 1993) . The yeast strain EGY48 expressing the bait was transformed with a human brain cDNA library (Clontech) to express fusion proteins of the 88-residue acidic E. coli peptide (B42) that activates transcription in yeast. Approximately 118 primary transformants were pooled and selected for growth in the absence of Leu and for β-galactosidase activity on X-gal plates. The sequence of cDNA fragments of positive clones were determined on both strands by using a Big Dye terminator cycle sequencing kit and a DNA sequencer, model 377 (Applied Biosystems).
Cell culture and stable cell lines
HCE-T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma) with Nutrient Mixture F-12 (Sigma) supplemented with 15% foetal bovine serum (Life Technologies, Inc.), 5 µg /mL bovine insulin (Roche Diagnostics Corp), 0.1 mg /mL cholera toxin (Calbiochem), and 10 ng /mL human epidermal growth factor (Upstate Biotechnology) at 37 °C in 5% CO 2 . H4IIE cells were cultured in a modified Eagle's medium (αMEM) (Life Technologies Inc.) supplemented with 10% foetal bovine serum at 37 °C in 5% CO 2 . HEK293 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) supplemented with 10% foetal bovine serum at 37 °C in 5% CO 2 . CHO-IR cells were cultured in Nutrient Mixture F-12 (Sigma) supplemented with 10% foetal bovine serum at 37 °C in 5% CO 2 .
Genes to Cells (2003) 9, 65 -79 77 PS120 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) supplemented with 10% foetal bovine serum at 37 °C in 5% CO 2 . PS120 cells were stably transfected with mutant AMPK subunits, either R70Qγ (AMPK activating) or GST-K45Rα1 (a dominant negative inhibitor), by a previously published method (Hamilton et al. 2001) . Cell incubation, measurement of AMPK activity and immunoblotting of AMPK subunits was performed as indicated (Hamilton et al. 2001) . 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) were purchased from Sigma.
Medium
Complete Minimum Eagle's medium salt solution [referred to as MEM AA(+)/G(+)] contained 5.5 mm d-glucose and amino acids as follows (in mg/L): Arg, 126.4; Cys, 24.02; Glu, 292; Ile, 52.46; Leu, 52.46; Lys, 73.06; Met, 14.92; Phe, 33.02; Thr, 47.64; Trp, 10.2; Tyr, 36.22; Val, 46.86; Ala, 8.9; Asn, 13.2; Asp, 13.3; Gln, 14.7; Gly, 7.5; Pro, 11.5; and Ser, 10.5 . In MEM AA(-)/G(+), all the amino acids were deprived from MEM AA(+)/G(+). In MEM AA(+)/G(-), d-glucose was deprived from MEM AA(+)/G (+). In MEM AA(-)/G(-), both total all the amino acids and d-glucose were deprived form MEM AA(+)/G(+).
Transfection
Transient transfection was performed by the lipofection method using LipofectAMINE (Life Technologies Inc.) or SuperFect (Qiagen) according to the manufacturer's protocol.
Immunoprecipitation and p70 S6 kinase assay p70 S6k activity was determined in immunoprecipitates using 40 S ribosomal subunits as substrate. Cells were lysed in ice-cold buffer A (Hara et al. 1998) , and the extracts were centrifuged at 10 000 g for 20 min. Aliquots of the supernatants were subjected to immunoprecipitation with the anti-p70 S6kα antibody. The immunoprecipitates were washed twice with buffer A containing 0.5 m NaCl and twice with 20 mm MOPS, pH 7.2, 10 mm β-glycerophosphate. The p70 S6 kinase assay was performed in the reaction mixture [50 mm MOPS, pH 7.2, 12 mm MgCl 2 , 2 mm EGTA, 1 mm DTT, 10 mm β-glycerophosphate, 0.5 mm PKI, 0.5 A260 units of 40 S ribosomal subunits, and 10 mm ATP, 2 µCi of [γ- The reaction was continued for 30 min at 30 °C. The p70 S6 kinase assay was terminated by adding SDS sample buffer followed by SDS-PAGE and autoradiography. The radioactivity was quantified with a BAS-2500 Bioimaging analyser (Fuji). Immunoblotting was performed using the anti-p70 S6k antibody as a primary antibody and Protein A-HRP (Bio-Rad) as a second probe, and visualized by the ECL method.
Immunoprecipitation and AMPK Assay
AMPK activity was determined in immunoprecipitates by using a synthetic peptide, HMRSAMSGLHLVKRR (referred to as SAMS peptide) as substrate . The immunoprecipitates using the AMPK α1 antibodies were washed twice with lysis buffer containing 100 mm NaCl, 50 mm Tris/HCl, pH 7.4, 50 mm NaF, 5 mm NaPPi, 1% Na-deoxycholate, 1% Triton X-100, 1 mm EDTA, 1 mm EGTA, 20 mm β-glycerophosphate, 1 mm DTT, 1 mm phenylmethylsulphonyl fluoride, 2 µg/mL aprotinin, 1 µm leupeptin. The immunoprecipitates were washed twice with lysis buffer, twice in 4× AMPK assay buffer containing 240 mm Na-HEPES, pH 7.0, 480 mm NaCl, 10 mm β-glycerophosphate, 4 mm DTT. The AMPK kinase assay was performed in 1× AMPK assay buffer (5 mm MgCl 2 , 2 mm EGTA, 1 mm DTT, 10 mm β-glycerophosphate, 0.2 mm AMP, 200 µm SAMS peptide, 20 µm ATP, 5 µCi of [γ-32 P]ATP). The reaction was continued for 20 min at 30 °C. The SAMS peptide kinase assay was terminated by the addition of 20 mm EDTA and 1.0 mm ATP. The reaction mixtures were spotted on to P81 phosphocellulose paper, followed by washes in 75 mm phosphoric acid. 32 P-labelled peptides were measured by Cerenkov counting.
